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Prolactinomas are the most common hormone-secreting pi-
tuitary adenomas. Prolactinomas account for nearly 30–40
percent of all the pituitary adenomas. Although it affects in-
dividuals over a wide age range, it is more common in 20–
40-year-old female patients, who are in their reproductive
age. Prolactinomas may cause hypogonadism, menstrual
cycle dysfunction (oligomenorrhea or amenorrhea) and in-
fertility (luteal phase abnormalities or anovulation) in pre-
menopausal women. When pregnancy is excluded,
hyperprolactinemia in approximately 10 to 20 percent of the
patients results in amenorrhea. Women with untreated pro-
lactinomas are generally unable to achieve pregnancy, as
the hyperprolactinemia affects the pulsatility of go-
nadotropin-releasing hormone (GnRH) and diminishes folli-
cle-stimulating hormone (FSH) as well as luteinizing
hormone (LH) secretion. The sum of these effects induces
amenorrhea, infertility, and hypogonadism, thereby posing
difficulties in fertility. Therefore, in most women prolactin-
oma is diagnosed prior to conception. However, ovulation
and fertility usually improve after proper diagnosis and
treatment of prolactinoma. Therefore, during the surveil-
lance of these patients, the onset of pregnancy is a com-
mon phenomenon. Management of these pregnancies may
sometimes be challenging and require a multidisciplinary
approach involving an endocrinologist, a gynecologist, a ra-
diologist and an experienced neurosurgeon in order to
achieve the best outcomes both for the patient as well the
infant. In this report, the authors aim to summarize the
consensus statements and the current guidelines for clinical
practice.
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Prolaktinomalar en sık görülen fonksiyonel hipofiz adenomları
olup tüm hipofiz adenomlarının yaklaşık %30-40 kadarını olu-
şturmaktadır. Her yaşta görülebilmekle birlikte 20-40 yaşları
arasındaki üreme çağındaki kadınlarda daha sık ortaya
çıkmaktadırlar. Prolaktinomada klinik tablo prolaktin düzey-
lerinin yüksekliği ile ilişkili olup galaktore ve gonadal fonksi-
yonlar üzerindeki sekonder etkiler sonucu ortaya çıkmaktadır.
Premenapozal kadınlarda hipogonadizm, menstruel siklus bo-
zuklukları (oligomenore ya da amenore) ve infertilite (luteal
faz defekti ya da anovulasyon) ile prezente olabilmektedir.
Hiperprolaktinemi, gebelik olmaksızın gelişen amenore ne-
denlerinin yaklaşık %10-20 kadarını oluşturmaktadır. Yüksek
serum prolaktin düzeyleri, gonadotropin salgılatıcı hormon
düzeylerini baskılayarak luteinizan hormon (LH) ve follikül sti-
mulan hormon (FSH) salgısını azaltarak menstruel siklus dü-
zensizlikleri ve hipogonadizme neden olduğundan tedavi
edilmeyen prolaktinomalı kadınlarda genellikle fertilitede
azalma söz konusudur. Bu nedenle prolaktinoma hastalarında
tanı, gebelik öncesi fertilite tetkikleri sırasında da konulabil-
mekte olup çoğunlukla konsepsiyon öncesinde ortaya
çıkmaktadır. Ancak prolaktinomanın doğru tanı ve tedavisi
sonrası genellikle ovulasyon ve fertilite düzeldiğinden, pro-
laktinoma hastalarının takipleri sırasında gebelik gelişimi de
nadir rastlanılan bir durum değildir. Sonuç olarak prolakti-
noma tedavisi sırasında araya giren gebeliklerin yönetimleri
sırasında bir takım zorluklarla karşılaşılabileceğinden endok-
rinolog, jinekolog, radyolog ve tecrübeli bir beyin cerrahisi
uzmanı tarafından multidisipliner bir yaklaşımla ele alınmaları
önerilmektedir. Bu derlemede mevcut klinik kılavuzlar ve
konsensus önerilerinin ışığında prolaktinoma ve gebelik ko-
nusundaki güncel yaklaşımlar özetlenmektedir.
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Prolactinomas are the most common out of all
the hormone-secreting pituitary adenomas.
Women with untreated prolactinomas are not
able to achieve pregnancy, as the hyperpro-
lactinemia affects the pulsatility of GnRH, dimin-
ishes FSH and LH secretion and induces
amenorrhea, infertility, and hypogonadism,
thereby posing difficulties in fertility (1). For this
reason, in most cases, prolactinoma is diagnosed
prior to conception. Nevertheless, ovulation and
fertility are normally improved by proper diagno-
sis and treatment. As a result, prolactinomas in a
pregnant woman are certainly challenging and
require a multidisciplinary approach involving an
endocrinologist, a gynecologist, a radiologist and
an experienced neurosurgeon to achieve the best
outcome. In this report, the authors aim to sum-
marize the consensus statements and the current
guidelines for clinical practice.
Guideline Recommendations
Regarding Preconception Period in
Patients with Prolactinomas
The risk of enlargement of a microprolactinoma
during pregnancy is nearly 1.5–4.5% with symp-
tomatic growth occurring in about 2% of the
cases. However, the risk of symptomatic enlarge-
ment of a macroprolactinoma is greater than 15%
(2, 3). The currently available dopamine agonists
(DAs) include bromocriptine, cabergoline, and
quinagolide (the latter is not approved for use in
the United States). It should be noted that the
restoration of ovulation, once DA therapy has
been started, occurs even before normopro-
lactinemia is achieved and the patient should be
informed about this outcome (4). In women who
are treated before conception, DA may also in-
duce shrinkage of the pituitary tumor (a reduc-
tion of greater than 25% is expected in the tumor
size in around 70% of the patients) (5).
■ Achieving a normalization of PRL levels and a
tumor size <10 mm before conception is recom-
mended for macroadenomas (6, 7).
■ In women of childbearing age, the use of me-
chanical contraception should be advised once
drug treatment has been initiated for macroade-
nomas. This is because ovulation and fertility
may rapidly be recovered after the normalization
of PRL levels (6, 8).
■ Transsphenoidal adenomectomy may be an op-
tion for women with microadenoma or macroade-
noma that is either intolerant or refractory to
Das, or prepregnancy tumor debulking by sur-
gery (thereby decreasing the risk of clinically sig-
nificant enlargement during pregnancy) would be
an option in cases of macroadenomas that do not
decrease in size with DA treatment or in those
who cannot tolerate bromocriptine or cabergoline
(6, 8). Transsphenoidal surgery may also cause
hypopituitarism, thus requiring the subsequent
use of assisted reproduction techniques such as
induction of ovulation with gonadotropins and
lifelong hormone replacement therapy (6-9). It is
for this reason that resumption of the DA is prob-
ably less harmful to the mother and the fetus as
compared to surgery (6). Therefore, the team-
work of multidisciplinary specialists is required
for the careful planning of pregnancy in women
with prolactinoma. Ideally, this should arise be-
fore conception, so that a full assessment of the
risks and benefits of DA therapy can be assessed
during pregnancy (10).
■ Whenever pregnancy is planned or detected in
macroadenomas, cabergoline should be discon-
tinued and bromocriptine should be introduced
although this drug also crosses the placental bar-
rier (6). Bromocriptine is the “oldest” of all the
dopamine agonists and has been tested more ex-
tensively than the other compounds, but there is
far less published experience with cabergoline
(8). Therefore, bromocriptine has been shown to
be safe for use during early gestation (up to the
first four weeks after conception, a critical period
for early organogenesis).
■ In women with microprolactinomas who want
to become pregnant, the use of clomiphene cit-
rate or gonadotropin therapy is suggested when
ovulation cannot be restored by DAs alone (6).
Guideline Recommendations
Related to pregnancy in
Patients with Prolactinoma
■ Women with prolactinomas must be instructed
to discontinue DA therapy as soon as they dis-
cover that they are pregnant (6-8, 10). In se-
lected patients with macroadenomas who are on
DA therapy and become pregnant and who have
not had prior tumor debulking by surgery, it may
be sensible to continue DA throughout the preg-
nancy, especially if the tumor is invasive or is
abutting the optic chiasm (6, 8, 10).
■ When symptomatic tumor growth occurs (pres-
ence of a headache or visual deterioration),
treatment with bromocriptine should be
restarted, if previously discontinued (6, 8). If the
enlarged tumor does not respond to reinstitution
with DA therapy within 2–3 weeks, transsphe-
noidal surgery (in the second trimester) or deliv-
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ery (if the pregnancy is far enough) must be con-
sidered (6-8, 10).
■ There is no evidence of increased teratogenic-
ity associated with the use of bromocriptine or
cabergoline during pregnancy (6, 8, 10).
Quinagolide, on the other hand, has shown a
poor safety profile in the relatively small number
of pregnancies that have been reported, and it
should not be prescribed to women who wish to
become pregnant (8).
■ In pregnant patients with prolactinomas, per-
forming serum prolactin measurements during
pregnancy is not recommended. This is for the
reason that in normal pregnancy, serum prolactin
levels increase 10-fold, reaching levels of 150 to
300 g/Liter by term (6-8).
■ In general, microprolactinomas and macropro-
lactinomas that are localized to the sella do not
undergo symptomatic growth during pregnancy,
therefore the use of routine pituitary MRI during
pregnancy is not recommended in these patients.
Because the risk of symptomatic tumor growth is
low, these patients may be followed up by clini-
cal examination during each trimester, unless
there is clinical evidence of tumor growth by
symptoms such as headaches or visual deterio-
ration (6-10). However, formal assessment of the
visual fields in macroprolactinoma should be per-
formed every three months or even more fre-
quently if the adenoma prior to conception is
close to the optic chiasm (8). When such clinical
manifestations appear, imaging must be per-
formed with unenhanced MRI. If the growth of
the pituitary mass is identified, re-institution of
DA (preferably bromocriptine) for the remainder
of the pregnancy may provide a control over the
tumor and in addition, monthly clinical assess-
ment is required (including visual fields).There-
fore, the onset of a new or a worsening
headache, or a change in vision or both, man-
dates the urgent performance of formal visual
field testing and a pituitary MRI without the use
of gadolinium (6-8).
Guideline Recommendations
Related to the Postpartum Period in
Patients with Prolactinoma
■ Women wishing to breastfeed their infants
should not be given DA because the resulting de-
crease in serum PRL levels will impair lactation.
There are no data available suggesting that breast-
feeding leads to an increase in tumor size (6, 7).
■ The spontaneous remission of hyperprolactine-
mia has only been reported in women with mi-
croprolactinomas. In these cases, long-term
discontinuation of treatment with DAs after birth,
along with regular monitoring for at least five
years may be considered (6).
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